Full Press Release Details
InMed to Present INM-901
Data at Alzheimer's Association
International Conference (AAIC) 2025
British Columbia - July 28, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"),
a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet
medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's
Association International Conference (AAIC) 2025, the world's leading
forum for Alzheimer's disease ("AD") and dementia research.
Data will be presented in a scientific poster
entitled, "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD
Mouse Model Study". The Alzheimer's disease preclinical study measured hippocampal RNA expression, inflammatory markers,
immunohistochemistry and behavioral differences following long-term treatment with INM-901 and as compared to healthy and to untreated
diseased subjects in a well-established model.
This latest study evaluates INM-901 in the well-established
5xFAD AD mouse model, using a longer treatment duration and subjects with more advanced disease to validate and expand upon previous findings,
which have demonstrated improvements in cognitive function, anxiety-related behavior, and sensory responsiveness.
of INM-901 Long-term 5xFAD study:
Alzheimer's Association International Conference (AAIC)
Location: Toronto, Canada
Website: https://aaic.alz.org/
Presentation poster will be available on InMed's
website following the conference.
Dr. Eric Hsu, SVP, Preclinical Research &
Development at InMed, commented, "The latest data continues to build on mounting preclinical evidence of the potential of INM-901
as a multi-targeted treatment candidate for Alzheimer's disease. INM-901 demonstrates a differentiated therapeutic approach in mitigating
Alzheimer's pathology and we are excited to share the results from this study with the Alzheimer's disease community at the
INM-901: Targeting multiple biological pathways
in Alzheimer's disease
INM-901 is a proprietary small molecule drug candidate
under development for the treatment of AD, with multiple mechanisms of action targeting key pathological features of the disease. Key
The Alzheimer's Association International
Conference ( AAIC') is a premier global event dedicated to advancing research and innovation in the fields of dementia and
cognitive health. This annual gathering unites scientists, medical professionals, and thought leaders from across the globe to share the
most recent discoveries, developments, and best practices in the field. Topics range from groundbreaking research to new care techniques,
all focused on improving early diagnosis, managing risks, and enhancing approaches to Alzheimer's and related diseases.
Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the
CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological
indications. For more information, visit www.inmedpharma.com.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release
includes, but is not limited to, statements about: the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's,
marketability and uses for INM-901.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-Q, in Item 1A. of the
Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.